Abstract:Background Overexpression of Aurora A and B has been reported in a wide range of tumor types, including gastric cancer. Anti-angiogenesis has been considered as an important therapeutic modality in advanced gastric cancer. Here we identified a novel compound TY-011 with promising antitumor activity by targeting mitotic kinases (Aurora A and B) and angiogenic receptor tyrosine kinase (VEGFR2). Methods HTRF® KinEASE™ assay was used to detect the effect of TY-011 against Aurora A, Aurora B and VEGFR2 activities. Docking simulation study was performed to predict the binding mode of TY-011 with Aurora A and B kinases. CCK-8 assay was used to test cell growth. Cell cycle and cell apoptosis was analyzed by flow cytometry. Gastric cancer cell xenograft mouse models were used for in vivo study. TUNEL kit was used to determine the apoptosis of tumor tissues. Immunohistochemistry analysis and HUVEC tube formation assay were performed to determine the anti-angiogenesis ability. Immunofluorescence and western blot were used to test protein expression. Results TY-011 was identified as a potential Aurora A and B inhibitor by HTRF® KinEASE™ assay. It effectively inhibited cellular Aurora A and B activities in a concentration-dependent manner. TY-011 occupied the ATP-binding site of both Aurora A and B kinases. TY-011 demonstrated prominent inhibitory effects on proliferation of gastric cancer cells. TY-011 treatment induced an obvious accumulation of cells at G2/M phase and a modest increase of cells with >4 N DNA content, which then underwent apoptosis. Meaningfully, orally administration of TY-011 demonstrated superior efficacy against the tumor growth in gastric cancer cell xenograft, with ~90% inhibition rate and 100% tumor regression at 9 mg/kg dose, and TY-011 did not affect the body weight of mice. Interestingly, we observed that TY-011 also antagonized tumor angiogenesis by targeting VEGFR2 kinase. Conclusions These results indicate that TY-011 is a well-tolerated, orally active compound that targets mitosis and angiogenesis in tumor growth, and provides strong preclinical support for use as a therapeutic for human gastric cancers.

In vitro and in vivo study of BZG-4000: Anti-tumoral activity of human hepatocellular carcinoma

Effect of BZG-4000, a novel multi-targeted kinase inhibitor with potent anticancer activity, on a hepatocellular carcinoma xenograft model

A Novel Multitarget Kinase Inhibitor BZG with Potent Anticancer Activity in Vitro and Vivo Enhances Efficacy of Sorafenib Through PI3K Pathways in Hepatocellular Carcinoma Cells.

Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases

Antitumour Effects of Tetrazanbigen Against Human Hepatocellular Carcinoma Qgy-7701 Through Inducing Lipid Accumulation in Vitro and in Vivo

Inhibitory Effect of EGFR Antisense Oligodeoxynucleotide on Human Hepatoma Cell Line.

Design, synthesis, biological evaluation and docking study of novel quinazoline derivatives as EGFR-TK inhibitors

A Preclinical Evaluation of a Novel Multikinase Inhibitor, SKLB-329, As a Therapeutic Agent Against Hepatocellular Carcinoma.

Apoptosis Induction of ZBB-006, a Novel Synthetic Diterpenoid, in the Human Hepatocellular Carcinoma Cell Line HepG2 in Vitro and in Vivo.

A novel anticancer agent, SKLB70359, inhibits human hepatic carcinoma cells proliferation via G0/G1 cell cycle arrest and apoptosis induction.

Synthesis,biological activity evaluation and mechanism of action of novel bis-isatin derivatives as potential anti-liver cancer agents

A Cell-Based Screen for Anticancer Activity of 13 Pyrazolone Derivatives

Novel Small Molecular Compound AE-848 Showed Potent Inhibitory Activity Against Human Hepatoblastoma Cells

Novel protein kinase inhibitor TT-00420 inhibits gallbladder cancer by inhibiting JNK/JUN-mediated signaling pathway

SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.

Synthesis of novel oxazol-5-one derivatives containing chiral trifluoromethyl and isoxazole moieties as potent antitumor agents and the mechanism investigation

Mass Spectral Analysis of the Multikinase Inhibitor BZG and Its Metabolites and Analysis of Their Binding to Vascular Endothelial Growth Factor Receptor-2

SKLB70326, a Novel Small-Molecule Inhibitor of Cell-Cycle Progression, Induces G0/G1 Phase Arrest and Apoptosis in Human Hepatic Carcinoma Cells

Indole Hydrazide Compound ZJQ-24 Inhibits Angiogenesis and Induces Apoptosis Cell Death Through Abrogation of AKT/mTOR Pathway in Hepatocellular Carcinoma

Anti-tumor Activities and Mechanism Study of Α-Pinene Derivative in Vivo and in Vitro

Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo